Combining azacitidine with venetoclax (Venclexta) significantly increased event-free survival (EFS) vs intensive induction ...

Transitioning the dose of axatilimab (Niktimvo) from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks appeared feasible in ...

The combination of carfilzomib (Kyprolis) plus lenalidomide (Revlimid) and dexamethasone (KRd) improved progression-free ...

The addition of epcoritamab to R2 significantly reduced the risk of death or disease progression in patients with relapsed/refractory follicular lymphoma.

Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

From clinical trials, to psychosocial needs, to care transitioning, adolescent and young adult patients with cancer face ...

The FDA has approved lisocabtagene maraleucel (liso-cel; Breyanzi) for the treatment of adult patients with relapsed or ...

Elranatamab-bcmm (Elrexfio) demonstrated poorer progression-free survival (PFS) but greater response rates vs eclistamab-cqyv (Tecvayli) in patients with relapsed/refractory multiple myeloma according ...

Nearly one-third of families of children receiving treatment for acute lymphoblastic leukemia (ALL) developed what researchers described as “catastrophic” financial toxicity during therapy, according ...

The FDA has approved pirtobrutinib (Jaypirca) treatment for adults with relapsed/refractory chronic lymphocytic leukemia or ...

After a radical hysterectomy and pelvic lymphadenectomy for early-stage cervical cancer, patients often face decisions about ...